WallStreetZenWallStreetZen

NASDAQ: HLTH
Cue Health Inc Stock Forecast, Predictions & Price Target

Analyst price target for HLTH

Based on 1 analyst offering 12 month price targets for Cue Health Inc.
Min Forecast
$0.50+244.83%
Avg Forecast
$0.50+244.83%
Max Forecast
$0.50+244.83%

Should I buy or sell HLTH stock?

Based on 1 analyst offering ratings for Cue Health Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HLTH stock forecasts and price targets.

HLTH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-10

1 of 1

Forecast return on equity

Is HLTH forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
19.16%

Forecast return on assets

Is HLTH forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

HLTH revenue forecast

What is HLTH's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$54.6M-23.04%
Avg 2 year Forecast
$117.7M+65.98%
Avg 3 year Forecast
$252.2M+255.6%
HLTH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HLTH revenue growth forecast

How is HLTH forecast to perform vs Health Information Services companies and vs the US market?
Company
41.25%
Industry
13.45%
Market
9.03%
HLTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HLTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HLTH vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
HLTH$0.15$0.50+244.83%Hold
BFRG$2.86N/AN/A
STRM$0.34N/AN/A
AKLI$0.24N/AN/A
ATPC$0.24N/AN/A

Cue Health Stock Forecast FAQ

Is Cue Health Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HLTH) stock is to Hold HLTH stock.

Out of 1 analyst, 0 (0%) are recommending HLTH as a Strong Buy, 0 (0%) are recommending HLTH as a Buy, 1 (100%) are recommending HLTH as a Hold, 0 (0%) are recommending HLTH as a Sell, and 0 (0%) are recommending HLTH as a Strong Sell.

If you're new to stock investing, here's how to buy Cue Health stock.

What is HLTH's revenue growth forecast for 2024-2026?

(NASDAQ: HLTH) Cue Health's forecast annual revenue growth rate of 41.25% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 13.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.03%.

Cue Health's revenue in 2024 is $70,936,000.On average, 1 Wall Street analysts forecast HLTH's revenue for 2024 to be $8,654,197,562, with the lowest HLTH revenue forecast at $8,654,197,562, and the highest HLTH revenue forecast at $8,654,197,562. On average, 1 Wall Street analysts forecast HLTH's revenue for 2025 to be $18,664,026,548, with the lowest HLTH revenue forecast at $18,664,026,548, and the highest HLTH revenue forecast at $18,664,026,548.

In 2026, HLTH is forecast to generate $39,985,103,367 in revenue, with the lowest revenue forecast at $39,985,103,367 and the highest revenue forecast at $39,985,103,367.

What is HLTH's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: HLTH) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of N/A.

What is HLTH's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HLTH price target, the average HLTH price target is $0.50, with the highest HLTH stock price forecast at $0.50 and the lowest HLTH stock price forecast at $0.50.

The Wall Street analyst predicted that Cue Health's share price could reach $0.50 by Nov 10, 2024. The average Cue Health stock price prediction forecasts a potential upside of 244.83% from the current HLTH share price of $0.15.

What is HLTH's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: HLTH) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.